S302: COST-EFFECTIVENESS OF KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

類似資料

• P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2
  著者:: M. L. Wang, 等
  出版事項: (2022-06-01)
• Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
  著者:: Enver Aydilek, 等
  出版事項: (2023-09-01)
• P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
  著者:: A. Bock, 等
  出版事項: (2022-06-01)
• A CASE OF RELAPSED REFRACTORY MANTLE CELL LYMPHOMA PRESENTING WITH SKIN LESIONS
  著者:: asli odabasi giden, 等
  出版事項: (2024-05-01)
• Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
  著者:: Alan S. Wayne, 等
  出版事項: (2022-10-01)